How shifts in excitation-inhibition balance may lead to psychiatric disorders
In a special issue of Biological Psychiatry titled "Cortical Excitation-Inhibition Balance and Dysfunction in Psychiatric Disorders", guest editors Dr. Alan Anticevic and Dr. John Murray, both of Yale University, bring together seven reviews that highlight advancements in understanding the balance of excitatory and inhibitory signaling in the brain, and what might happen when it goes awry.
Alterations in excitation/inhibition (E/I) balance constitute an emerging theme in clinical neuroscience, wrote Anticevic and Dr. John Lisman of Brandeis University in a commentary accompanying the special issue. The effects of E/I imbalance stretch across diagnostic boundaries, as indicated by the variety of psychiatric disorders addressed in the reviews, including schizophrenia, autism spectrum disorder, major depressive disorder, and bipolar disorder.
Presenting both human and animal studies, the reviews summarize research on the developmental aspects of E/I regulation and how alterations in circuit stability and compensatory mechanisms with negative effects may emerge when the E/I balance tips. In particular, multiple reviews frame the disturbances in the E/I balance around altered glutamate synaptic development–the excitatory arm of the E/I balance — and present hypotheses for how those developmental alterations may lead to impaired structural and functional circuitry in the brain. A case is made for the need for a combination of approaches, including computational neuroscience, imaging, pharmacological, and genetic studies, in addition to consideration of the coregulation of excitation and inhibition (rather than focusing on the neurotransmitter systems independently) to explain the role of E/I imbalance in psychiatric disorders.
The collection of reviews not only collate findings aimed at improving our understanding of how these developmental changes and potential negative consequences arise, but also explore how to restore E/I balance. Restoration aims to alleviate the subsequent dysfunctional neural activity that manifests as clinical symptoms, such as impaired working memory in schizophrenia. This is explored, for example, through pharmacological manipulation of glutamate modulation on E/I circuitry.
Notes for editors
The special issue is "Cortical Excitation-Inhibition Balance and Dysfunction in Psychiatric Disorders", Biological Psychiatry, volume 81, issue 10 (May 2017), published by Elsevier.
Copies of papers included in this issue are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or biol.ps[email protected]
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 140 Psychiatry titles and 11th out of 256 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2015 Impact Factor score for Biological Psychiatry is 11.212.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880